News | February 23, 2010

Session Examines Anti-Platelet Therapies During ACC

February 23, 2010 – Experts in anti-platelet therapy will offer their insights and interpretations on emerging agents in comparison to current therapy at an evening session during ACC 2010 from 6:30-9:15 p.m., Sunday, March 14 at the Hyatt Regency Atlanta, 265 Peachtree St., NE, Atlanta.

While dual oral anti-platelet therapy with aspirin and a thienopyridine is a standard treatment in patients with acute coronary syndromes (ACS) and after percutaneous coronary intervention (PCI), many questions remain about its optimal use. Due to the need for improved anti-platelet therapy, new agents are presently under investigation.

Speakers will discuss choices in therapy, current evidence, new guidelines and the risk of ischemic and bleeding complications. They will also discuss evidence related to proton pump inhibitors (PPIs).

The faculty includes Deepak Bhatt, M.D. (chair); ?Jeffrey Anderson, M.D.;?Dominick Angiolillo, M.D.;?Richard Becker, M.D.;?Marc Sabatine, M.D., MPH; ?Lars Wallentin, M.D., Ph.D.; and?W. Douglas Weaver, M.D.
The session is sponsored by AstraZeneca.

For more information:

Related Content

Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Overlay Init